GLP-1 drugs are revolutionizing obesity treatment in the U.S.
These medications can lead to significant weight loss, changing lives.
Cost implications raise questions about access and equity in healthcare.
The societal perception of obesity is shifting with new treatment options.
Healthcare providers face ethical dilemmas in prescribing these drugs.